Literature DB >> 26550397

A T-cell prolymphocytic leukemia case with central nervous system involvement.

Umit Yavuz Malkan1, Gursel Gunes1, Okan Yayar1, Haluk Demiroglu1, Aysun Yesilirmak2, Aysegul Uner2.   

Abstract

T-cell prolymphocytic leukemia (T-PLL) is an aggressive mature T cell neoplasm that typically involves peripheral blood, bone marrow, lymph nodes and spleen. It is a rare disease that comprises 2-5% of mature lymphocytic leukemia in adults. Here we present a T-PLL patient with CNS involvement. A 74-year-old man admitted to a hospital in April 2014 with vomiting. He was diagnosed as chronic lymphocytic leukemia (CLL) and R-CVP (Rituximab, cyclophosphamide, vincristine and prednisolone) chemotherapy protocol was started. After the first two cycles of chemotherapy, the patient's mental functions improved. However after the 3(rd) cycle of chemotherapy was given in July 2014 the general situation of the patient deteriorated and ptosis of the left eye and facial paralysis developed. Then the patient was referred to our medical center. An MR of the brain revealed linear contrast enhancement around the bilateral 3(rd), 7(th) and 8(th) cranial nerves which indicated cranial involvement by the lymphoproliferative process (Figure 1). Cerebrospinal fluid cytological examination confirmed the diagnosis. Based on these and bone marrow aspiration and biopsy findings a diagnosis of T-PLL was rendered (Figure 3). In September 2014 the patient died suddenly due to a cardiac arrest. Differential diagnosis is very important in T-PLL. Both T-PLL and chronic lymphocytic leukemia (CLL) may present with splenomegaly and lymphocytosis as well as circulating prolymphocytes in blood. Typical CLL cells are like mature lymphocytes with dense nucleus and aggregated chromatin. To conclude, CNS involvement in T-PLL is a rare finding and differential diagnosis of T-PLL is very important.

Entities:  

Keywords:  T-cell prolymphocytic leukemia; central nervous system involvement

Year:  2015        PMID: 26550397      PMCID: PMC4613082     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  7 in total

1.  The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication.

Authors:  Gülsüm Emel Pamuk; Fulya Oz Puyan; Ercüment Unlü; Erman Oztürk; Muzaffer Demir
Journal:  Leuk Res       Date:  2008-10-16       Impact factor: 3.156

2.  Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire.

Authors:  R Garand; J Goasguen; A Brizard; J Buisine; A Charpentier; J F Claisse; E Duchayne; M Lagrange; C Segonds; X Troussard; G Flandrin
Journal:  Br J Haematol       Date:  1998-11       Impact factor: 6.998

3.  Meningeal involvement in B-cell chronic lymphocytic leukemia: report of two cases.

Authors:  M L Wang; L Y Shih; P Dunn; M C Kuo
Journal:  J Formos Med Assoc       Date:  2000-10       Impact factor: 3.282

4.  Involvement of central nervous system in prolymphocytoid transformation of chronic lymphocytic leukemia.

Authors:  Hideyuki Kuwabara; Heiwa Kanamori; Hirotaka Takasaki; Maki Takabayashi; Satoshi Yamaji; Naoto Tomita; Katsumichi Fujimaki; Shin Fujisawa; Yoshiaki Ishigatsubo
Journal:  Leuk Lymphoma       Date:  2003-07

5.  Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation.

Authors:  L Garderet; H Bittencourt; A Kaliski; M Daniel; P Ribaud; G Socié; E Gluckman
Journal:  Eur J Haematol       Date:  2001-02       Impact factor: 2.997

6.  Multifocal deficits due to leukemic meningoradiculitis in chronic lymphocytic leukemia.

Authors:  C Denier; G Tertian; V Ribrag; P Lozeron; C Bilhou-Nabera; T Lazure; K Abbed; C Lacroix; D Adams
Journal:  J Neurol Sci       Date:  2008-12-19       Impact factor: 3.181

7.  Regression of intracerebral lesions in T prolymphocytic leukaemia treated with intravenous deoxycoformycin.

Authors:  F Brito-Babapulle; D Huang; P Lavender; D Galton; D Catovsky
Journal:  Eur J Haematol       Date:  1988-02       Impact factor: 2.997

  7 in total
  2 in total

1.  Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia.

Authors:  Fares Alsawah; Lydia Benitez; Sarah Choi; Bernard Marini; Anthony Perissinotti; Amy Skyles; Patrick Burke; Kristen Pettit; Ashley Crouch; Heather Fox; Dale Bixby
Journal:  Blood Adv       Date:  2019-11-12

Review 2.  Central Nervous System Involvement of Natural Killer and T Cell Neoplasms.

Authors:  Ashley E Aaroe; Kathryn S Nevel
Journal:  Curr Oncol Rep       Date:  2019-03-27       Impact factor: 5.945

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.